Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17121645 | 0.90 | KMT2A (0.60) | MAPTKMT2AMEN1HTTPKM | |
| SCHEMBL17121765 | 0.88 | MAPT (0.56) | MAPTKMT2AMEN1HTTPKM | |
| SCHEMBL17121763 | 0.88 | MAPT (0.75) | MAPTKMT2AMEN1HTTPKM | |
| SCHEMBL19443068 | 0.88 | MAPT (0.66) | MAPTKMT2AMEN1HTTPKM | |
| SCHEMBL17121762 | 0.88 | KMT2A (0.56) | MAPTKMT2AMEN1HTTPKM | |
| SCHEMBL17119987 | 0.88 | KMT2A (0.55) | MAPTKMT2AMEN1HTTPKM | |
| SCHEMBL17121644 | 0.87 | KMT2A (0.54) | MAPTKMT2AMEN1HTTPKM | |
| SCHEMBL17120012 | 0.86 | SMN1; SMN2 (0.54) | MAPTKMT2AMEN1HTTPKM | |
| SCHEMBL17120006 | 0.86 | MAPT (0.53) | MAPTKMT2AMEN1HTTPKM | |
| SCHEMBL17120018 | 0.86 | KMT2A (0.53) | MAPTKMT2AMEN1HTTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185801-A1 | USE OF SMALL MOLECULE INHIBITORS TO KLF10 FOR MODULATION OF T REGULATORY CELLS AND CANCER IMMUNOTHERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-06-16 | — | — | US | disclosed |
| US-20180021277-A1 | ANTI-VIRULENCE COMPOSITIONS AND METHODS | CASE WESTERN RESERVE UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
| US-20180021277-A1 | ANTI-VIRULENCE COMPOSITIONS AND METHODS | CASE WESTERN RESERVE UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
| US-9782363-B2 | Anti-virulance compositions and methods | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-10 | — | — | US | disclosed |
| US-9782363-B2 | Anti-virulance compositions and methods | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170121318-A1 | USE OF SMALL MOLECULE INHIBITORS TO KLF10 FOR MODULATION OF T REGULATORY CELLS AND CANCER IMMUNOTHERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121318-A1 | USE OF SMALL MOLECULE INHIBITORS TO KLF10 FOR MODULATION OF T REGULATORY CELLS AND CANCER IMMUNOTHERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20150265550-A1 | ANTI-VIRULANCE COMPOSITIONS AND METHODS | CASE WESTERN RESERVE UNIVERSITY | 2015-09-24 | — | — | US | disclosed |
| US-20150265550-A1 | ANTI-VIRULANCE COMPOSITIONS AND METHODS | CASE WESTERN RESERVE UNIVERSITY | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121318-A1 | USE OF SMALL MOLECULE INHIBITORS TO KLF10 FOR MODULATION OF T REGULATORY CELLS AND CANCER IMMUNOTHERAPY | KLF10, KLF5, ICOS | MAPT 2531/4885KMT2A 273/4885MEN1 2657/4885 |
| US-20180021277-A1 | ANTI-VIRULENCE COMPOSITIONS AND METHODS | LTA, CUTA, ELANE | MAPT 4434/4885KMT2A 3508/4885MEN1 4350/4885 |
| US-20220185801-A1 | USE OF SMALL MOLECULE INHIBITORS TO KLF10 FOR MODULATION OF T REGULATORY CELLS AND CANCER IMMUNOTHERAPY | KLF10, KLF5, ICOS | MAPT 2531/4885KMT2A 273/4885MEN1 2657/4885 |
| US-20150265550-A1 | ANTI-VIRULANCE COMPOSITIONS AND METHODS | VAPA, SRRT, ANTXR2 | MAPT 4706/4885KMT2A 2094/4885MEN1 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.